Gonadorelin

Gonadorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH). It acts on GnRH receptors (GnRHR) in pituitary gonadotrophs, stimulating synthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby regulating the hypothalamic-pituitary-gonadal (HPG) axis.

Male Fertility: Amplifies endogenous pulsatile GH when combined with GHRH
Female Fertility: Enhanced ovulation induction; 26.9% pregnancy rate in intrauterine insemination cycles; lower OHSS incidence (≈61%)
Hormonal Regulation: Testosterone normalization in men during treatment; evaluation of pituitary gonadotrope capacity
Reproductive Health: Promotes secondary sexual characteristic development within 6–12 months
Clinical Monitoring: Live birth rates comparable to standard therapy (OR 1.02); pituitary function assessment

Liu Y, Gong B, Xie W, et al. The pulsatile gonadorelin pump induces earlier spermatogenesis than cyclical gonadotropin therapy in congenital hypogonadotropic hypogonadism men. Am J Mens Health. 2019;13(5):1557988319871375. DOI
Al-Inany HG, Youssef MA, Ayeleke RO, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4(4):CD001750. DOI
Bhasin S, Steiner BS, Handelsman DJ, et al. Hormonal effects of GnRH agonist in men. J Clin Endocrinol Metab. 1987;64(3):548–555. DOI
Rashidi B, Haghollahi F, Shariat M, Zayerii F. Effect of GnRH agonist vs hCG on final oocytes for ovulation triggering in IUI. Int J Reprod BioMed. 2017;15(7):433–438. DOI
Pitteloud N, Boepple PA, DeCruz S, et al. The fertile eunuch variant of idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2002;87(9):4460–4465. DOI

$68.00

Per Unit

In stock